3rd CMO Quality Oversight & Risk Management
16 Apr 2013 - 17 Apr 2013 - Boston, MA, USA
With outsourcing on the rise, the FDA and regulatory agencies worldwide are focusing greater attention on product quality. Regulatory agencies from the FDA to ANVISA are heavily scrutinizing where Active Pharmaceutical Ingredients are coming from as the level of oversight increases. Furthermore, a number of large pharmaceutical companies recently have lost billions of dollars when faced with consent decrees. Are you confident that GMP standards are being met throughout the manufacturing process? Can you afford the cost of a consent decree?
ExL Pharma’s 3rd CMO Quality Oversight and Risk Management Conference is the premier event for gaining best practice strategies to effectively oversee and manage CMOs. Hear from key leaders at big pharma companies as well as pharma contract manufacturing service providers to find out how risk is being managed on both the sponsor and vendor sides, while quality is ensured through robust quality agreements and compliance with multiple GMP standards.